RegeneRx Biopharmaceuticals, Inc.
http://www.regenerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RegeneRx Biopharmaceuticals, Inc.
Sandoz Partner Samsung Bioepis Settles On Stelara In US
Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.
Dry Eye Crossover Study Could Allow Aldeyra A Quick Response To US FDA’s CRL For Reproxalap
Aldeyra’s bid to rely on a single Phase III trial after an initial one failed is rejected by FDA, but firm already has a special protocol assessment under review for a trial that could provide the symptom data it says agency needs to approve the RASP modulator in dry eye.
Aldeyra Plans Quick Response To FDA’s CRL For Reproxalap
Aldeyra already has a special protocol assessment under review at the FDA for a trial to provide the symptom data the agency said is needed for approval of the RASP modulator in dry eye disease.
Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention
Office of Inspector General analysis could add momentum to reforms of the rebating system.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice